Panagora Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Panagora Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$441K	Buy	47,328 +349	+0.7%	+$3.04K	﹤0.01%	881
2025 Q4	$352K	Hold	46,979	–	–	﹤0.01%	955
2025 Q3	$408K	Buy	+46,979	New	+$281K	﹤0.01%	863
2024 Q4	–	Sell	-100,973	Closed	-$1.09M	–	1178
2024 Q3	$1.09M	Sell	100,973 -253,884	-72%	-$4.21M	0.01%	704
2024 Q2	$7.45M	Buy	354,857 +252,789	+248%	+$6.34M	0.04%	259
2024 Q1	$3.25M	Sell	102,068 -1,603	-2%	-$40.9K	0.02%	434
2023 Q4	$2.1M	Buy	103,671 +27,983	+37%	+$368K	0.01%	546
2023 Q3	$964K	Buy	+75,688	New	+$1.27M	0.01%	791

Other funds holding FDMT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Panagora Asset Management's FDMT Position: Q1 2026 in Review

Panagora Asset Management increased its 4D Molecular Therapeutics (FDMT) stake by 0.74% in Q1 2026, buying an estimated $3.04K and bringing the position to 47,328 shares worth $441K. The position accounts for ﹤0.01% of the portfolio, ranked #881.

Panagora Asset Management first reported a position in FDMT in Q3 2023 and has held it in 8 quarters since. The position peaked at $7.45M in Q2 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

Panagora Asset Management held 47,328 shares of 4D Molecular Therapeutics worth $441K as of Q1 2026.
Panagora Asset Management bought 349 4D Molecular Therapeutics shares in Q1 2026, an estimated $3.04K.
4D Molecular Therapeutics made up ﹤0.01% of Panagora Asset Management's portfolio in Q1 2026, its #881 holding.
Panagora Asset Management first reported a position in 4D Molecular Therapeutics in Q3 2023 and has held it in 8 quarters since.
Panagora Asset Management's 4D Molecular Therapeutics position peaked at $7.45M in Q2 2024.
152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Panagora Asset Management's 13F filing for Q1 2026, filed 14 May 2026.